DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Gram-Negative Infections: How Will U.S. Payer and Prescriber Receptivity to Novel Antibiotics Shape the Market for These Therapies? | Physician & Payer Forum | US | 2014
Gram-negative infections (GNIs) represent a high-value segment of the antibiotic market and are often treated in the hospital setting. Infections due to Gram-negative pathogens (GNPs) are…
Physician &Crohn’s Disease and Ulcerative Colitis: U.S. Physician and Payer Perspectives on Established and Recently Launched Biologics, Emerging Novel Agents and Biosimilars | Payer Forum | US | 2014
Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that commonly feature treatment with biological therapies. The U.S. CD market…
Painful Diabetic Neuropathy | Treatment Algorithms | Claims Data Analysis | US | 2014
In 2013, painful diabetic neuropathy (PDN) affected more than 3.4 million people in the United States. Similar to postherpetic neuralgia, PDN has also served—and continues to serve—as a gateway…
Type 2 Diabetes (The Dynamic Type 2 Diabetes Landscape: Market Access Levers and Barriers amid Increasing Austerity in the EU5) | Physician & Payer Forum | EU5 | 2014
The European type 2 diabetes market is contending with the convergence of innovative pharmaceutical offerings, such as Johnson & Johnson’s Invokana, AstraZeneca’s Xigduo, and Takeda’s Vipidia…
Healthcare Reform and Behavioral Health: Impact of Health Exchanges and Medicaid Expansion on Prescribing for Schizophrenia, Major Depression, and Bipolar Disorder | Physician & Payer Forum | US | 2014
The Affordable Care Act has expanded access to insurance coverage to millions and has reformed health insurance requirements to assure more-comprehensive coverage of behavioral health and…
Biosimilars Advisory Service: Acceptance of Biosimilars Across Physician Specialties | Biosimilars Advisory Service | US/EU | 2014
The fledgling biosimilars industry is full of uncertainties and nuances that differ by country, therapeutic specialty, and molecule. Securing a positive return on lengthy biosimilar development…
Umeclidinium Bromide Vilanterol (Anoro Ellipta) (COPD) (Wave 1) | LaunchTrends | US | 2014
This three-wave LaunchTrends report series will track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (…
Population Health Management in Type 2 Diabetes: What Does This Approach Mean for Specific Diabetes Brands? | Physician & Payer Forum | US | 2014
Population health management (PHM) represents one of the long-term goals of the healthcare industry: building upon the patient-centered medical home concept to provide proactive support to a…
